BMY

Late-cycle big pharma navigating a steep loss-of-exclusivity (LOE) wall: Revlimid already eroding, Eliquis US exclusivity ends 2028 and Opdivo IV by 2028 (subQ extension partial offset). 1B, actinium-225 radiopharma platform). Cobenfy is the swing factor: first novel schizophrenia MoA in decades, ADEPT trials extend label into Alzheimer-related psychosis and adjunctive use.

5B by 2025, additional $2B by 2027) defends earnings through LOE trough. Trades at low-single-digit P/E on consensus 2026 numbers with ~5% dividend.

BULL

- Cobenfy first-in-class schizophrenia launch; label expansion (Alzheimer psychosis, adjunctive bipolar) could 3-5x peak sales vs initial estimates

- Eliquis subQ formulation + IRA Medicare negotiation impact already in numbers; downside priced

- $22B M&A pipeline rebuild starting to contribute (Krazati, RayzeBio actinium platform vs $NVS Pluvicto)

- ~5% dividend yield with investment-grade balance sheet; aggressive cost program defends FCF

BEAR

- Eliquis (~$12B/yr) and Opdivo (~$9B/yr) IV LOE concentrated 2028-2030; Cobenfy + acquisitions unlikely to fully offset on current ramps

- M&A track record mixed: Celgene deal still digesting goodwill writedowns; Karuna/Mirati/RayzeBio assets unproven at scale

- IRA Medicare price negotiation hits Eliquis Jan 2026 (~$3B revenue exposure)

- Pipeline depth thin behind Cobenfy; reliant on M&A cadence to refill, balance sheet capacity tightening